Mason Street Advisors LLC bought a new position in Syneos Health Inc (NASDAQ:SYNH) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 28,301 shares of the company’s stock, valued at approximately $1,005,000.
Several other institutional investors also recently bought and sold shares of the company. Northwestern Mutual Investment Management Company LLC purchased a new stake in shares of Syneos Health in the 1st quarter valued at approximately $409,000. Commonwealth Equity Services LLC bought a new position in shares of Syneos Health during the 1st quarter worth about $527,000. Cardinal Capital Management LLC CT bought a new position in Syneos Health during the 1st quarter valued at about $12,637,000. Rubric Capital Management LP bought a new position in Syneos Health during the 1st quarter valued at about $3,891,000. Finally, Clinton Group Inc. bought a new position in Syneos Health during the 1st quarter valued at about $637,000.
Several brokerages have recently commented on SYNH. Zacks Investment Research upgraded shares of Syneos Health from a “hold” rating to a “buy” rating and set a $47.00 price target for the company in a research report on Wednesday, May 16th. Mitsubishi UFJ Financial Group started coverage on shares of Syneos Health in a research note on Friday, April 20th. They issued an “overweight” rating and a $50.00 price target on the stock. ValuEngine lowered shares of Syneos Health from a “hold” rating to a “sell” rating in a research note on Monday, April 2nd. Barclays reissued an “equal weight” rating and issued a $43.00 price objective (up previously from $40.00) on shares of Syneos Health in a research report on Thursday, March 1st. Finally, SunTrust Banks upped their price target on shares of Syneos Health to $55.00 and gave the stock a “buy” rating in a research report on Thursday, March 1st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the company. Syneos Health has an average rating of “Buy” and an average target price of $50.40.
Shares of Syneos Health traded down $0.25, reaching $47.30, on Tuesday, Marketbeat reports. The company had a trading volume of 11,890 shares, compared to its average volume of 746,185. The stock has a market capitalization of $4.91 billion, a P/E ratio of 24.33, a price-to-earnings-growth ratio of 1.16 and a beta of 0.83. Syneos Health Inc has a one year low of $31.10 and a one year high of $61.10. The company has a current ratio of 1.09, a quick ratio of 1.09 and a debt-to-equity ratio of 1.01.
Syneos Health (NASDAQ:SYNH) last released its earnings results on Wednesday, May 9th. The company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.51 by $0.04. The business had revenue of $761.00 million during the quarter, compared to the consensus estimate of $767.24 million. Syneos Health had a negative net margin of 5.50% and a positive return on equity of 8.79%. The business’s quarterly revenue was up 201.9% compared to the same quarter last year. equities analysts predict that Syneos Health Inc will post 2.36 EPS for the current fiscal year.
Syneos Health Company Profile
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.